Successful treatment with adapted high dose methotrexate in a hemodialysis patient with primary central nervous system lymphoma: 100 mg/m2 seems sufficient
Justine Solignac(Inserm), Mickaël Bobot(Inserm), Raphaëlle Fanciullino(Inserm), Laure Farnault(Aix-Marseille Université), Geoffroy Venton(Inserm), Sylvain Choquet(Sorbonne Université), Philippe Brunet(Inserm), Thomas Robert(Aix-Marseille Université)
Cited by 3
Related Papers
Gene Expression Profiling of Primary Cutaneous Melanoma and Clinical Outcome
|JNCI Journal of the National Cancer Institute|2006|480
Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines
|Journal of the American Heart Association|2020|298
ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
|Blood|2021|157
Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
|Supportive Care in Cancer|2017|77
Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
|UCL Discovery (University College London)|2022|76